XFOR
X4DNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
The bull case remains a funded execution story: a positive U.S. WHIM franchise, a pending European decision, and stated runway into 2028 give the company time to work through clinical and commercialization milestones.
Posture
Defensive
Lead driver
Sentiment
What changed
Sentiment remains the lead driver in the composite, 7D delta +13.1.
What can break
4WARD enrollment slippage would push out the later readout and keep the stock event-driven.
Momentum
25
Value
41
Sentiment
70
Setup hits (3d)
0 · Net Neutral
AI TargetsBase $4.50 · Bull $8.50 · Bear $2.00
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-05-20 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net Neutral
Target $11.60
Why
Momentum25 · Δ7d +9.5
Value41 · Δ7d -0.1
Sentiment70 · Δ7d +13.1
So what
Weak posture (Net Neutral). Prioritize risk control and patience.
Lead driver: Sentiment · See AI snapshot
Momentum
25
26% active weight
Current posture
7d trendImproving
Δ7d
+9.5
Δ21d
-0.0
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
70
34% active weight
Current posture
7d trendImproving
Δ7d
+13.1
Δ21d
+5.1
Why this grade
Composite grade D. Momentum 24.5 / Value 41.1 / Sentiment 69.8
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$360.3M
Beta
0.46
Shares Out
94.32M
P/E (TTM) · Derived
-2.0
P/S (TTM)
9.88
P/FCF (TTM) · Derived
-0.58
Rev YoY
-90.6%
EPS YoY
-490.0%
Gross Margin
+79.0%
Op Margin
-291.1%
Net Debt
-$176.52M
Current Ratio
10.18
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology